id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15367 R63243 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Motor mean score ≤ 86 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.99 [0.19;5.18] C excluded (control group) |
2/21 7/73 | 9 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15368 R63256 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Motor mean score ≤ 86 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.16 [0.20;6.87] C | 2/21 4/48 | 6 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9716 R34581 |
Deshmukh (Carbamazepine), 2016 | Vineland-II Adaptative Behavior Scales - Low and moderately low in the motor skills domain | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 0.81 [0.19;3.41] | 8/97 8/104 | 16 | 97 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9937 R35713 |
Videman (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2016 | Griffiths Mental Developmental Scale - Locomotor (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
0.20 [0.03;1.27] excluded (control group) |
-/9 -/8 | - | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9936 R35707 |
Videman (Carbamazepine) (Controls unexposed, disease free), 2016 | Griffiths Mental Developmental Scale - Locomotor (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) | 2.37 [0.66;8.52] | -/9 -/59 | - | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9696 R34509 |
Bromley (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Dyspraxia (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.19 [0.01;4.87] C excluded (control group) |
0/50 1/30 | 1 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9699 R34525 |
Bromley (Carbamazepine) (Controls unexposed, disease free), 2013 | Dyspraxia (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
4.31 [0.08;220.05] C excluded (control group) |
0/50 0/214 | 0 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9702 R34541 |
Bromley (Carbamazepine) (Controls unexposed, sick), 2013 | Dyspraxia (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.52 [0.01;26.73] C | 0/50 0/26 | 0 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9710 R34553 |
Cohen (Carbamazepine), 2011 | Motor Index score the Bayley Scales of Infant Development (BSID-II)) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes extrapolated (cont. endpoint) | 0.87 [0.45;1.71] | -/51 -/62 | - | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9737 R34693 |
Thomas b (Carbamazepine), 2008 | Impaired Motor Development Quotient < 84 (The Developmental Assessment Scale (DAS II)) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.13 [0.47;2.73] C | 31/101 9/32 | 40 | 101 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9747 R34796 |
Viinikainen (Carbamazepine) b, 2006 | Touwen's test Neurological dysfunction/impairment | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.46 [0.04;5.79] C | 1/13 2/13 | 3 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9593 R33974 |
Adab (Carbamazepine), 2004 | Schedule of Growing Skills II (SGSII) locomotion delay | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.42 [0.01;22.11] C | 0/42 0/18 | 0 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9639 R34291 |
Ornoy (Carbamazepine), 1996 | Combined motor score (of Bayley and McCarthy tests) | throughout pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Matched | 0.97 [0.45;2.07] | -/41 -/47 | - | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 9 studies | 1.01 [0.69;1.47] | 65 | 425 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine) (Controls unexposed, disease free; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine; 6: Carbamazepine; 7: Carbamazepine) ; 8: Carbamazepine; 9: Carbamazepine;
Asymetry test p-value = 0.6226 (by Egger's regression)
slope=0.1157 (0.2424); intercept=-0.2148 (0.4174); t=0.5147; p=0.6226
excluded 9696, 9699, 9937, 15367